drugset
drugset / Trial / NCT06563999

Neoadjuvant Umbrella Trial for Patients With Unresectable Stage III NSCLC Harboring Rare Mutations.

NCT06563999 ↗

Phase 2 Recruiting 120 enrolled Sun Yat-sen University
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This umbrella trial directed by next generation sequencing (NGS) includes patients with treatment-naive unresectable stage III non-small-cell lung cancer (NSCLC). The aim of the umbrella study is to evaluate the efficacy of induction NGS-directed targeted therapies followed by surgery for stage III NSCLC patients whose tumor harbors a rare mutation.

Timeline

Start
2024-11-01
Primary completion
2027-11-01
Completion
2029-11-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Crizotinib Small molecule 300 mg Oral
Subject Dabrafenib Small molecule 150 mg Oral
Subject Ensartinib Small molecule 225 mg Oral
Subject Glecirasib Small molecule 800 mg Oral
Subject Larotrectinib Small molecule 100 mg Oral
Subject Pralsetinib Small molecule 400 mg Oral
Subject Pyrotinib Small molecule 400 mg Oral
Subject Savolitinib Small molecule 400 mg Oral
Subject Savolitinib Small molecule 600 mg Oral
Subject Sunvozertinib Small molecule 300 mg Oral
Subject Trametinib Small molecule 150 mg Oral

Indications

lung carcinoma